The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 295.00
Ask: 299.00
Change: 0.00 (0.00%)
Spread: 4.00 (1.356%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hutchmed China confident after being added to SEC list

Thu, 31st Mar 2022 10:04

(Sharecast News) - Hutchmed China updated the market on its status under the United States 'Holding Foreign Companies Accountable Act' on Thursday.

The AIM-traded firm said that, following its implementation of rules under the act, the US Securities and Exchange Commission (SEC) added Hutchmed to its list of issuers identified under the act.

It was provisionally named as an SEC-identified Issuer on 8 March, following the filing of its annual report on 3 March.

The SEC estimated that 273 registrants might be identified under the act as part of its review of registrants in 2020.

"We anticipate that other similarly-situated US-listed companies with operations in Hong Kong and other parts of China will be added once they file their annual reports with the SEC," the board said in its statement.

"As the company continues to monitor market developments and evaluate all strategic options, with the appropriate counsel and guidance, it would like to note that this update has no impact on business operations."

Hutchmed said it understood that the motivation behind the act was to ensure appropriate transparency and disclosure, so that investors would be able to make informed investment decisions.

"This we fully support and have been committed to ever since our initial listing in London in 2006.

"As always, we will continue complying with relevant laws and regulations in all the jurisdictions we are listed.

"Furthermore, we are working to maintain communication with the China Securities Regulatory Commission (CSRC) to understand if there are further updates on their discussions with the US authorities regarding how China-based companies may be able to meet the requirements of the act."

Hutchmed said it would continue to evaluate its options to remain listed in the US, including assessing the merits of appointing an auditor outside of China if and when the contribution of its international business to the group exceeded its China business.

At 1235 BST, shares in Hutchmed China were down 3.49% in London, at 290.5p.

More News
3 Jan 2023 13:47

Hutchmed China completes enrolment for solveplenib clinical trial

(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for 'ESLIM-01', a pivotal phase 3 clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (ITP) in China.

Read more
3 Jan 2023 10:28

Hutchmed completes patient enrolment for ITP clinical trial in China

(Alliance News) - Hutchmed (China) Ltd on Tuesday said it has completed patient enrolment for its clinical trial exploring potential treatment therapies for adults with primary immune thrombocytopenia in China.

Read more
19 Dec 2022 19:29

TRADING UPDATES: Tekcapital's MicroSalt plans IPO in 2023

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
15 Nov 2022 11:30

Hutchmed refocuses strategy away from early-stage studies

(Sharecast News) - Hutchmed China updated the market on its strategy on Tuesday, following an "in-depth evaluation" of the business.

Read more
15 Nov 2022 10:52

Hutchmed China to shift strategy toward advanced assets in pipeline

(Alliance News) - Hutchmed (China) Ltd announced on Tuesday it will shift focus towards its most advanced assets from its internal developed pipeline, following an evaluation of the business.

Read more
14 Nov 2022 16:55

LONDON MARKET CLOSE: Europe ends higher but New York struggles

(Alliance News) - European equities surrendered some afternoon gains but made a bright start to the week on Monday, shaking off hawkish noise from the US Federal Reserve, while investors waited with bated breath for the outcome of talks between the leaders of the world's two leading economies.

Read more
14 Nov 2022 14:20

IN BRIEF: Hutchmed sees positive results for gastric cancer drug

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. Explains the drug met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase-three study in 703 patients, which the firm says is "clinically meaningful". Fruquintinib also shows a "statistically significant improvement" in secondary endpoints including objective response rate, disease control rate, and improved duration of response, Hutchmed adds. The study looked at patients with advanced gastric or gastroesophageal junction adenocarcinoma, a type of cancer.

Read more
14 Nov 2022 10:27

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
14 Nov 2022 09:40

Hutchmed reports positive results from recent fruquintinib study

(Sharecast News) - Hutchmed China announced initial results from the 'FRUTIGA' phase 3 study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma on Monday.

Read more
27 Oct 2022 14:27

IN BRIEF: Hutchmed begins phase II/III trial of fruquintinib

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins randomised, open-label, active-controlled phase II/III trial of fruquintinib combination with sintilimab in China. The trial will explore the combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma - the most common type of kidney cancer. The first patient in China received the dose on Thursday, it says.

Read more
10 Oct 2022 10:24

Hutchmed begins sovleplenib trial for anaemia treatment in China

(Alliance News) - Hutchmed China Ltd on Monday said it has begun a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune haemolytic anaemia in China.

Read more
8 Sep 2022 11:02

Hutchmed posts positive results for CRC cancer treatment

(Alliance News) - Hutchmed China Ltd on Thursday said that its fruquintinib treatment reduced risk of death by 34% in metastatic colorectal cancer patients.

Read more
9 Aug 2022 10:04

Hutchmed notes dosing of first participant in IMG-004 study

(Alliance News) - Hutchmed China Ltd on Tuesday said it has dosed its first participant in its global phase one trial of IMG-004.

Read more
8 Aug 2022 12:42

Hutchmed upbeat on latest study results for colorectal cancer treatment

(Sharecast News) - Hutchmed China announced on Monday that the "pivotal" global phase three trial evaluating the investigational use of 'fruquintinib' met its primary endpoint of overall survival in patients with advanced, refractory metastatic colorectal cancer (CRC).

Read more
8 Aug 2022 11:32

UPDATE: Hutchmed, AstraZeneca move lung cancer drug to phase 3 trial

(Alliance News) - Hutchmed China Ltd and AstraZeneca PLC on Monday said preliminary results from the Savannah phase 2 trial showed a promising objective response rate, and has moved the drug into phase 3 trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.